Biofluid-Based Assay for Predicting Drug Binding ID: 2024-049

A revolutionary assay that predicts drug binding on a proteomic scale with residue-specific resolution, enhancing drug discovery processes.

Technology Overview

This technology introduces a novel biofluid-based assay designed to predict drug binding on a proteomic scale, offering residue-specific resolution without the need for protein purification. Utilizing protein folding stability, it detects drug-protein interactions by measuring changes in protein stability due to drug binding. This method is rooted in the groundbreaking work of H.J.L. Lin and colleagues, which quantified the structural stabilities of human blood plasma proteins.

Key Advantages

• Enables the assessment of drug binding in complex biological mixtures
• Provides residue-specific information on drug-protein interactions
• Eliminates the need for protein purification, streamlining the drug discovery process
• Offers a novel approach to understanding amyloid-driven pathologies

Problems Addressed

• Difficulty in assessing drug binding in complex mixtures due to the requirement of protein purification
• Lack of residue-specific information on drug-protein interactions
• Challenges in early diagnosis and prevention of amyloid-driven diseases like transthyretin-mediated amyloidosis

Market Applications

• Drug discovery and development in the pharmaceutical industry
• Diagnostic assays for early detection of amyloidosis and other protein misfolding diseases
• Biomedical research tools for studying protein stability and drug-protein interactions
• University research and commercial development through patent applications

Additional Information

Technology ID: 2024-049
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025